Saturday, July 11, 2026

pharma · No medical condition. · Generalized Myasthenia Gravis

Anaxis Pharma

Lacuna Pharma Pty is a pharma organization headquartered in Colmenar Viejo, AU. Primary therapeutic focus areas include No medical condition., Generalized Myasthenia Gravis, No therapeutic indication in the current trial

Melbourne, AU HQ
2017 Founded
7 Employees
TGA registrant Type
Company details
Status
Public
HQ
Melbourne, AU
Founded
2017
Employees
7
Programs
642
Drugs
673
Patents
0
Clinical program

Pirfenidone Solution for Inhalation

Phase 2 · small molecule · Interstitial Lung Diseases (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF)

Pirfenidone Solution for Inhalation for Interstitial Lung Diseases (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF) is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

← All Lacuna Pharma Pty Ltd projects Phase 2 small molecule active

Internal code AP01-005

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Lacuna Pharma Pty Ltd
Phase
Phase 2
Modality
small_molecule
Indication
Interstitial Lung Diseases (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF)
Status
active
Trials
1